GlaxoSmithKline Pharmaceuticals Limited
GLAXO · Pharma · NSE
₹2,103
Current Market Price
Fair Value (DCF)
₹1,896
Discount to FV
-9.8%
Updated 3h ago
YieldIQ Score
58/100
Piotroski F-Score
7/9
Economic Moat
Wide
Confidence
77%
ROE
45.7%
Debt/Equity
0.01
WACC
9.5%
Market Cap
₹35,629 Cr
Quality & Valuation
Neutral model outputs — no recommendations.
ROCE
64.1%
Return on capital employed
EV / EBITDA
25.5×
Enterprise multiple
Debt / EBITDA
0.0×
Leverage vs earnings
Interest Coverage
516.0×
EBIT covers interest
Current Ratio
2.03×
Short-term liquidity
Asset Turnover
0.92×
Revenue per ₹ of assets
Revenue CAGR (3Y)
5.8%
3-year revenue growth
Revenue CAGR (5Y)
—
5-year revenue growth
DCF Scenario Analysis
vs CMP ₹2,103.2
Bear case
Discount -104.6%
Base case
Discount -10.9%
Bull case
Discount +7.2%
Ratio Trends
GLAXO · last 9 annual periods
ROE
45.7%
ROCE
64.1%
Operating Margin
—
Debt / Equity
0.01×
PE
37.3×
EV / EBITDA
25.5×
Historical Financials
GLAXO · Annual, last 5 years· amounts in ₹Cr unless noted
| Metric | 2022 NSE_XBRL | 2023 NSE_XBRL | 2024 NSE_XBRL | 2025 yfinance | 2026 yfinance | CAGR |
|---|---|---|---|---|---|---|
| Revenue | ₹3264 Cr | ₹3226 Cr | ₹3442 Cr | ₹3749 Cr | ₹3822 Cr | +4.0% |
| EBITDA | ₹849 Cr | ₹904 Cr | ₹888 Cr | ₹1328 Cr | ₹1475 Cr | +14.8% |
| EBIT | ₹781 Cr | ₹838 Cr | ₹818 Cr | — | — | +1.2% |
| PAT | ₹1695 Cr | ₹611 Cr | ₹590 Cr | ₹928 Cr | ₹1036 Cr | -11.6% |
| EPS (diluted) | ₹22.48 | ₹35.87 | ₹34.83 | — | — | +11.6% |
| CFO | ₹811 Cr | ₹484 Cr | ₹582 Cr | ₹1290 Cr | ₹903 Cr | +2.7% |
| CapEx | ₹-34.6 Cr | ₹-44.0 Cr | ₹-31.2 Cr | ₹-24.7 Cr | ₹-55.3 Cr | — |
| FCF | ₹776 Cr | ₹440 Cr | ₹551 Cr | ₹1265 Cr | ₹848 Cr | +2.2% |
| Total Assets | ₹4633 Cr | ₹3327 Cr | ₹3557 Cr | ₹4108 Cr | ₹4324 Cr | -1.7% |
| Total Debt | ₹20.1 Cr | ₹15.5 Cr | ₹18.7 Cr | ₹10.0 Cr | ₹33.3 Cr | +13.5% |
| Shareholders' Equity | ₹2663 Cr | ₹1741 Cr | ₹1778 Cr | ₹1951 Cr | ₹2267 Cr | -3.9% |
CAGR computed across the visible window. Signs reverse if start value is zero or negative.
Peer Comparison
GLAXO vs 1 closest peer by market-cap band
| Peer | MoS | Score | Verdict | ROE | PE |
|---|---|---|---|---|---|
 PFIZER Pfizer Limited | -18.5% | 43 | High Risk | 17.2% | — |
Click a ticker to view its fair-value analysis.
Dividend History
12 ex-dividend events on file. Source: NSE corporate-actions feed.
Total paid (5Y)
₹295.00/sh
Last payout
2026-05-29
₹57.00
Peak payout
₹90.00
Trailing yield
2.71%
Amounts parsed from NSE subject lines. Percent-of-face-value declarations are converted using the per-ticker face value (defaults to ₹10).
AI Analysis Summary
Model-generated description of metrics. Not investment advice. GlaxoSmithKline Pharmaceuticals Limited (GLAXO.NS) trades at 2103.20 vs a model fair value of 1896.20, a gap of -9.8%. Piotroski F-score:...
Read full AI analysis →Reverse DCF
Market-implied growth
What FCF growth is priced in →
Risk Analysis
Volatility & drawdown
Risk profile of GLAXO →
DuPont
ROE decomposition
Why ROE is what it is →
Technicals
RSI, MACD, MAs
Reference indicators →
News & Filings
Recent activity
BSE filings + news for GLAXO →
Compare
Head-to-head with peers
Compare GLAXO side by side →
Run Full Interactive Analysis
Interactive DCF sliders, sensitivity heatmap, peer comparison, and more.
Analyse GLAXONow →Model estimates using publicly available data. Not investment advice. YieldIQ is not registered with SEBI as an investment adviser or research analyst. Past performance does not guarantee future results.